Supplementary figure: Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use

These are peer-reviewed supplementary materials for the article 'Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use' published in the Journal of Comparative Effectiveness Research.Supplementary Figure 1: Time to biologic initiation during the 2-year follow-up period among patients with 2 years of follow-upSupplementary Table 1: Patient demographic characteristics and prescriber specialtySupplementary Table 2: Baseline comorbiditiesSupplementary Table 3: Baseline medication useSupplementary Table 4: Baseline healthcare utilization, and costsSupplementary Table 5: Number of index medication fills before biologic initiation during the 1-year follow-up periodSupplementary Table 6: First biologic medication used during the 1-year follow-up period among apremilast patients who initiated biologicSupplementary Table 7: First biologic medication used during the 1-year follow-up period among methotrexate patients who initiated biologicSupplementary Table 8: Biologic initiation adjusted resultsAim: To compare rates of biologic initiation after commencing treatment with apremilast (APR) versus methotrexate (MTX) in systemic-naive patients with psoriasis (PsO). Methods: This was a retrospective cohort study of systemic-naive patients with PsO who initiated treatment with APR or MTX between 1 January 2015 and 31 March 2018. Outcomes: Adjusted rates of biologic initiation during follow-up were compared by logistic and Cox regressions. Results: APR initiators had 58% lower likelihood of biologic initiation (odds ratio: 0.42; 95% CI: 0.37–0.48; p